This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Need extra cash? Learn where to find side jobs for quick income that can help you reach your financial goals.
18,819 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Allstate beats on underwriting and returns capital, while Progressive shows growth but a steadier combined ratio. The...
A high-stakes debate is unfolding around SpaceX and its heavy short interest. This article breaks down what it means ...
Tech giant Alphabet leads a Thursday rally as its Gemini AI rollout gains traction. This piece breaks down what that ...
Gas prices climbed again this week, drawing a rare acknowledgment from Trump as investors weigh energy stocks and inf...
A missing, nationwide accounting of subsidies per affordable unit clouds the price tag of affordable housing. This re...
Finding value in semiconductors is tough, but a disciplined approach can spot opportunities amid rapid tech change. L...
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Bank of America signals a noticeable pullback in card use across its customers, adding to a growing picture of cautio...
Betterware de Mexico appears to be trading at a discount despite a growth plan centered on Latin America expansion an...
Analysts are scrutinizing Strategy’s STRC funding loop as the near-$100 par anchor tightens. A disruption could tempe...
Coinbase stock trades around the mid-180s as crypto markets swing. Analysts offer a wide range of year-end targets, h...